Rare Diseases
News
Bendamustine/rituximab combo proves viable for comorbid CLL
Combination bendamustine and rituximab offers an effective treatment option for older, sicker patients with chronic lymphocytic leukemia.
News
Don’t delay palliative care for IPF patients
The sharp decline in quality of life in IPF patients is similar to that seen in lung cancer patients, in contrast to the more gradual trend seen...
Conference Coverage
Genetic variant increases stroke risk in childhood cancer survivors
ATLANTA - Dr. Yadav Sapkota of St. Jude Children's Research Hospital discusses the identification of a genetic variant that is strongly associated...
Conference Coverage
CAR T cells target HER2 expression in advanced sarcomas
ATLANTA – Although HER2 expression in osteosarcoma and rhabomyosarcoma is too low for HER2-targeted therapies such...
Article
Promising New Approach for Treating Cystic Fibrosis
A longtime antifungal standard, amphotericin, may hold the key to reducing or even preventing the chronic infections that affect patients with...
Conference Coverage
VIDEO: Immunomodulators for inflammatory skin diseases
WASHINGTON - Off-label therapies discussed by Dr. Friedman include dapsone, hydroxychloroquine, and pentoxifylline.
News
Case report may link gluteal implants to lymphoma
On the heels of increased reports of breast implant–related anaplastic large cell lymphoma, researchers report a case of lymphoma that may be...
Original Research
Necrotizing Infection of the Upper Extremity: A Veterans Affairs Medical Center Experience (2008-2017)
Necrotizing infection of the upper extremity is a rare pathology with a substantial risk of amputation and mortality that...
Conference Coverage
BTK inhibitor calms pemphigus vulgaris with low-dose steroids
WASHINGTON – PRN1008 blocks BTK receptors on B cells, thus forestalling the B-cell mediated inflammatory cascade.
News
Histoplasmosis Manifests After Decades
Are immunocompromised patients ever out of the woods after the original health issue is resolved? A new study suggests not.